.Attribute Medication, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of patients along with HER2+ sophisticated breast cancer cells and active or even stable human brain metastases presented constant intracranial activity and also systemic effectiveness of T-DXd.